Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology.
Fiche du document
- doi: 10.1136/jitc-2020-002220
- issn: 2051-1426
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1136/jitc-2020-002220
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33589529
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2051-1426
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_838DD59A4F971
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Mots-clés
immunotherapySujets proches
Sterility Sterility in humans Involuntary childlessnessCiter ce document
B.C. Özdemir, « Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology. », Serveur académique Lausannois, ID : 10.1136/jitc-2020-002220
Métriques
Partage / Export
Résumé
Despite a significant amount of data on incidence and therapy of immune-related adverse events affecting virtually all organ systems, the potential impact of immune checkpoint inhibitors (ICIs) on gonadal function has not been sufficiently studied. The limited evidence available suggests that ICI-related primary hypogonadism due to orchitis as well as secondary hypogonadism due to hypophysitis are a potential risk for infertility. A systematic investigation of gonadal function under ICIs is warranted given the increasing application of ICIs in the adjuvant setting, among young adults and children and the possible influence of sex hormone levels on the efficacy and toxicity of ICIs.